UBS Group Portfolio holdings
UBS Group AG, formed through the 1998 merger of Union Bank of Switzerland and Swiss Bank Corporation with roots dating back to 1862, is a Swiss multinational investment bank and financial services firm headquartered in Zurich. Renowned for its dominance in wealth management, UBS serves high-net-worth individuals and families globally, managing trillions in assets, while also offering investment banking, asset management, and retail banking services in Switzerland. The firm has weathered significant challenges, including a major bailout during the 2008 financial crisis, but has since refocused on stability and sustainable growth, emphasizing digital transformation and ESG (environmental, social, governance) investing. With a strong European base and a global reach, UBS remains a cornerstone of the international financial landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.12B |
| 2 |
Apple
AAPL
|
+$1.08B |
| 3 |
Microsoft
MSFT
|
+$1.05B |
| 4 |
Nike
NKE
|
+$1.03B |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$821M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$389M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$383M |
| 3 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$348M |
| 4 |
PXD
Pioneer Natural Resource Co.
PXD
|
+$263M |
| 5 |
NRG Energy
NRG
|
+$237M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.8% |
| 2 | Financials | 8.25% |
| 3 | Healthcare | 6.4% |
| 4 | Consumer Discretionary | 5.85% |
| 5 | Communication Services | 4.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3351
Agios Pharmaceuticals
AGIO
$1.93B
| $2.99M | ﹤0.01% |
69,359
-101,526
| -59% | -$3.66M |
|
3352
Fortrea Holdings
FTRE
$1.75B
| $2.99M | ﹤0.01% |
128,010
-35,734
| -22% | -$1.11M |
|
3353
CALL
Qorvo
QRVO
$8.74B
| $2.98M | ﹤0.01% |
25,700
| – | – |
|
|
3354
PUT
Qorvo
QRVO
$8.74B
| $2.98M | ﹤0.01% |
25,700
| – | – |
|
3355
Myriad Genetics
MYGN
$312M
| $2.98M | ﹤0.01% |
121,887
-88,382
| -42% | -$1.94M |
|
3356
Atlas Energy Solutions
AESI
$1.41B
| $2.98M | ﹤0.01% |
149,507
-195,379
| -57% | -$4.36M |
|
3357
State Street Ultra Short Term Bond ETF
ULST
$526M
| $2.98M | ﹤0.01% |
73,617
-17,054
| -19% | -$689K |
|
3358
ICL Group
ICL
$6.85B
| $2.97M | ﹤0.01% |
694,036
+344,940
| +99% | +$1.62M |
|
3359
Brunswick
BC
$5.28B
| $2.97M | ﹤0.01% |
40,818
-3,319
| -8% | -$271K |
|
3360
CALL
State Street SPDR S&P Metals & Mining ETF
XME
$4.48B
| $2.97M | ﹤0.01% |
50,000
-1,530,000
| -97% | -$93.7M |
|
3361
Louisiana-Pacific
LPX
$5.49B
| $2.96M | ﹤0.01% |
35,999
-45,750
| -56% | -$3.82M |
|
3362
Bankunited
BKU
$3.36B
| $2.96M | ﹤0.01% |
101,081
+28,373
| +39% | +$790K |
|
|
EFC
3363
Ellington Financial
EFC
$1.71B
| $2.96M | ﹤0.01% |
244,709
-47,737
| -16% | -$562K |
|
3364
PUT
UBS Group
UBS
$176B
| $2.95M | ﹤0.01% |
100,000
| – | – |
|
3365
Victory Capital Holdings
VCTR
$6.65B
| $2.95M | ﹤0.01% |
61,853
+15,831
| +34% | +$775K |
|
|
CSGS
3366
DELISTED
CSG Systems International
CSGS
| $2.95M | ﹤0.01% |
71,604
-4,653
| -6% | -$206K |
|
3367
10x Genomics
TXG
$6.61B
| $2.95M | ﹤0.01% |
151,557
+97,290
| +179% | +$2.55M |
|
3368
Remitly
RELY
$5.14B
| $2.95M | ﹤0.01% |
243,187
+71,444
| +42% | +$1.11M |
|
3369
Kulicke & Soffa
KLIC
$4.78B
| $2.95M | ﹤0.01% |
59,899
-812,280
| -93% | -$38.2M |
|
3370
CALL
Kimberly-Clark
KMB
$36.5B
| $2.94M | ﹤0.01% |
21,300
| – | – |
|
|
GOGL
3371
DELISTED
Golden Ocean Group
GOGL
| $2.94M | ﹤0.01% |
213,200
-6,854
| -3% | -$94.7K |
|
|
TPH
3372
DELISTED
Tri Pointe Homes
TPH
| $2.93M | ﹤0.01% |
78,742
-24,089
| -23% | -$907K |
|
3373
Travel + Leisure Co
TNL
$4.7B
| $2.93M | ﹤0.01% |
65,185
-41,032
| -39% | -$1.84M |
|
3374
CALL
Canadian National Railway
CNI
$76.6B
| $2.93M | ﹤0.01% |
24,778
| – | – |
|
3375
Invesco Leisure and Entertainment ETF
PEJ
$308M
| $2.91M | ﹤0.01% |
64,173
-5,460
| -8% | -$244K |
|
Similar funds
UBS Group's Q2 2024 Portfolio in Review
As of Q2 2024, UBS Group held 10,501 positions worth $405B, up 0.81% from $402B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
UBS Group's Q2 2024 filing shows 1,231 new, 3,688 increased, 4,131 reduced and 1,043 closed positions. Its largest new stake was SLB Ltd: 10,925,731 shares worth $515M. The largest sale was BioMarin Pharmaceuticals, an estimated $389M.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 15% a quarter earlier, followed by Financials and Healthcare.
- UBS Group's largest Q2 2024 buy was SLB Ltd: 10,925,731 shares worth $515M.
- UBS Group added most to NVIDIA in Q2 2024, an estimated $1.12B increase.
- UBS Group's biggest Q2 2024 reduction was BioMarin Pharmaceuticals, cutting an estimated $389M.
- UBS Group fully exited Pioneer Natural Resource Co. in Q2 2024, selling an estimated $263M.
- UBS Group's ten largest holdings make up 18% of its $405B portfolio in Q2 2024.
- UBS Group opened 1,231 new positions and closed 1,043 in Q2 2024.
- UBS Group's portfolio value rose 0.81% quarter-over-quarter to $405B.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.